Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Cancer-associated fibroblasts (CAFs) are the predominant components of the tumor
microenvironment (TME) and influence cancer hallmarks, but without systematic …

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The accumulation of lipid peroxides is recognized as a determinant of the occurrence of
ferroptosis. However, the sensors and amplifying process of lipid peroxidation linked to …